Results 211 to 220 of about 102,229 (258)
Some of the next articles are maybe not open access.
Phosphodiesterase inhibitors in psychiatric disorders
Psychopharmacology, 2023Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi +5 more
openaire +2 more sources
Disaggregatory action of phosphodiesterase inhibitors
Pharmacological Research Communications, 1981Summary Papaverine and three hypotensive xanthines were shown to disaggregate platelet clumps in anaesthetized cats. The order of disaggregatory potency was: IMBX > papaverine > > aminophylline ≫ xantinol nicotinate. This effect was not associated with the release of prostacyclin. It is concluded that disaggregatory action of papaverine and xanthines
Ryszard J. Gryglewski +2 more
openaire +3 more sources
The new inotropic phosphodiesterase inhibitors
Archives Internationales de Physiologie et de Biochimie, 1984Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D El Allaf +2 more
openaire +3 more sources
Phosphodiesterase inhibitors in clinical urology
Expert Review of Clinical Pharmacology, 2013To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the ...
Markus A. Kuczyk +2 more
openaire +3 more sources
Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design, 2005An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Ashok Tehim +3 more
openaire +3 more sources
The role of phosphodiesterase inhibitors in impotence
Expert Opinion on Investigational Drugs, 1997Penile erection is mediated by nitric oxide (NO) and its second messenger cyclic guanosine monophosphate (cGMP). The activity of cGMP is modulated by the enzyme phosphodiesterase (PDE). The most important physiological isoform of the enzyme in the penis is PDE5.
openaire +3 more sources
Targeting cancer with phosphodiesterase inhibitors
Expert Opinion on Investigational Drugs, 2009For many cancers, there has been a shift from management with traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific targeted therapies that are used either alone or in combination with traditional chemotherapy and radiation therapy.
Ralph T. Schermuly +6 more
openaire +3 more sources
Phosphodiesterase Inhibitors: History of Pharmacology
2011The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as PDE.
Rolf Beume +3 more
openaire +3 more sources
Inhibitors of phosphodiesterase as cancer therapeutics
European Journal of Medicinal Chemistry, 2018Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in many physiological processes including visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function ...
Lan Bai +7 more
openaire +2 more sources
Chemotherapeutic potential of phosphodiesterase inhibitors
Current Opinion in Chemical Biology, 1998The application of molecular cloning has revealed the phenomenal diversity and complexity of the phosphodiesterase isoenzyme family. Thus, more than 30 human phosphodiesterases are now known; all are apparently necessary for the seemingly simple task of hydrolysing the 3'-ester bond of either cyclic adenosine monophosphate or cyclic guanosine ...
Gerald A Higgs, Martin J Perry
openaire +3 more sources